Abstract
We are pleased to be able to present this summary of the first century of Dr. Coley’s toxins prepared by Helen Coley Nauts. We believe you will agree that this is an objective scientific presentation particularly when one considers the criticism, frequently unfounded, which has been given Coley’s work in the past. Those reading this chapter and working in hyperthermia will find many parallels and similarities with their frustrations and peer criticisms as noted herein. Comparable modes of action will be found for those proposed to explain the benefits of hyperthermia. Possibly with today’s more detailed understanding of the intricate complex immune system, a logical basis can be offered for the “dramatic cures” which in themselves caused skepticism, and Coley’s results can be better understood. A study of Coley’s life’s work will lead to a better understanding of the problems, obstacles and potential solutions we have in hyperthermia and also I suspect that it will help our morale to realize that we are not the first or only ones to have criticisms heaped upon sound and meticulous work. It is gratifying that in recent years Coley is being recognized as the pioneer of cancer immunology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Nauts, H.C., Fowler, G.A. & Bogatko, G.H.: A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man. Acta Medica Scandinavia 145: Supplement 276. Stockholm, April 1953.
Nauts, H.D., Swift, W.E., & Colery, B.L.: The treatment of malignant tumors by bacterial toxins, as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Research 6: 205–216, 1946.
Nauts, H.D.: Beneficial effects of immunotherapy (bacterial toxins) on sarcoma of the soft tissues, other than lymphosarcome. End results in 186 determinate cases with microscopic confirmation of diagnosis–49 operable, 137 inoperable. Monograph #16. Cancer Research Institute, New York, 1975.
Nauts, H.D.: Osteogenic sarcoma: End results following immunotherapy (bacterial vaccines) 165 cases, or concurrent infections, inflammation or fever, 41 cases. Cancer Research Institute, Monograph #15. New York, 1975.
Coley, W.B.: The treatment of cancer. Guys’ Hosp. Gaz. 26: 72–14, 1911.
Nauts, H.C., Fowler, G.A.: End results in lymphosarcoma treated by toxin therapy alone or combined with surgery and/or radiation (87 cases) or with concurrent bacterial infection (14 cases). Monograph #6, New York Cancer Research Institute, Inc.*, New York, 1969.
Nauts, H.C.: The beneficial effects of bacterial infections on host resistance to cancer. End results in 449 cases. A study and abstracts of reports in the world medical literature (1775–1980) and personal communications. Cancer Research Institute, Monograph #8, 2nd Edition, 1980.
Nauts, H.C.: Bibliography of reports concerning the experimental or clinical use of Coley toxins (Streptococcus pyogenes and Serratia marmarcescens) 1893–1989. (394 references, including 143 by W.B. Coley). Published 1975,1977.1980.1982,1984,1985,1986, 1987, 1988, 1989.
Moullin, C.M.: The treatment of sarcomata by the injection of mixed toxins (Coley’s fluid). Brit. M.J. London 2: 451, 1898.
Coley, W.B.: Treatment of inoperable malignant tumors with toxins of erysipelas and the Bacillus prodigiosus. Trans. Amer. Surg. Assn. 12: 183–212, 1894.
Coley, W.B.: The influence of the Roentgen ray upon the different varies of sarcoma. Trans. Amer. Surg. Assn. 20:308–309, 1902. ( Also in Med. News. 81: 542–545.
Nauts, H.C.: Beneficial effects of acute concurrent infection, inflammation, fever or immunotherapy (bacterial toxins) on ovarian and uterine cancer. Cancer Research Institute, Monograph #17. New York. 1977. (122 pp.) and conference with Calkins, 1943.
Matagne, H.: Premiers essais de traitement des tumeurs malignes inoperables par les toxines de Coley: un cas de cancer gueri. Gaz. Med. Liege 8: 401–402, 1896. (See also: Rapport de la commission qui a ete chargee d’examiner le memoire de M. le Dr. H. Matagne, a Bruxelles, initule: Premiers essais traitement des tumeurs malignes inoperables par les toxines de Coley; un cas de cancer gueri. Bull. Acad. Roy. de Med. de Belg. (Brussels) 10: 275–278, 1896.
Matagne, H.: Traitement des tumeurs malignes inoperable par l’erysipele et par les toxines de Coley. Press Med. Belge, (Brussels) 51:603–607; 624–629; 633–639, 1899.
Matagne, H.: Les toxines de Coley employees dans le but de prevenir la recidive du cancer. Press Med. Belge 54: 1–3, 1901.
Matagne, H.: Presentation de cancereux gueris par les toxines de Coley, employees conjointement avec intervention chirurgicale. Presse Med. Belge. 57: 173–179, 1905.
Matagne, J.H.J.: Vers la guerison du cancer. Le Scalpel 104:504–544. 1951; and 106: 1387–1395, 1953.
Owens, J.F.: The use of toxins in the treatment of sarcoma, particularly of operable cases. Illinois State Med. Soc. Trans. (Chicago) 218–277, 1897. (also New Orleans, M. & S. J. 50: 1–8, 1897.
Coley, W.B.: The indications for the non–operable local treatment of tumors. The value of Toxins. Concord, N.H. Rep. Press Assn., 1896. (read before the New York State Medical Association, October 16, 1895. Reprint)
Editorial: J.A.M.A. Dec. 15, 1894; Coley’s reply Jan. 5, 1895.
Harmer, T.W.: A study of the efficiency of mixed toxins (Coley) in inoperable sarcoma. A critical analysis of 134 microscopically proven cases. Boston M. & S. J. 172: 331–338; 373–377; 411–416; 440–448, 1915.
Harmer, T.W.: Remarks upon the effects observed in the use of the mixed toxins (Coley) in certain cases of sarcoma. Boston M. & S. J. 171: 253–261, 1914.
Nauts, H.C.: Giant Cell Tumor of Bone: End results following immunotherapy (Coley toxins) alone or combined with surgery and/or radiation (66cases), or with concurrent infection (4 cases). Monograph #4, 2nd Edition, Cancer Research Institute, Inc., New York, 1975.
Nauts, H.D.: Immunological factors affecting incidence prognosis and survival in breast cancer. Part I: Factors affecting host resistance to breast cancer and therefore its incidence and response to treatment. Part II: The immunopotentiating effects of concurrent infections, inflammation or fever. Part III: Immunotherapy, effects of bacterial vaccines. Cancer Research Institute. Monograph #18, New York, 1984.
Coley, W.B.: Cancer of the testis; containing a report 64 cases, with special reference to 12 cases of cancer of the undescended testis. Trans. South Surg. & Gyn. Assn. 26:17–67, 1914. (Also in Ann. Surg. 62: 40–73, 1915 ).
Coley, W.B.: Primary neoplasms of the lymphatic glands including Hodgkin’s disease. Ann. Surg. 63: 35–70, 1916.
Coley, W.G. & Hoguet, J.B.: Melanotic cancer; with a report of ninety cases. Trans. Am. Surg. Assn. 34: 319–383, 1916.
Coley, W.B.: Multiple myeloma. Ann. Surg. 93:77–89, 1931. (Also in Trans. Amer. Surg. Assn. 48: 489–514, 1931 ).
Coley, W.B.: Endothelioma, or Ewing’s tumor. Am. J. Surg. 27: 7–18, 1935.
Fowler, G.A. & Nauts, H.D.: The apparently beneficial effects of concurren infections, inflammation or fever and of bacterial toxin therapy on neuroblastoma. New York Cancer Research Institute, Inc., Monograph #11, New York, 1970.
Fowler, G.A.: Beneficial effects of acute bacterial infections or bacterial toxin therapy on cancer of the colon or rectum. New York Cancer Research Institute, Monograph #10, New York, 1969.
Nauts, H.C.: Enhancement of natural resistance to renal cancer: Beneficia effects of concurrent infections and immunotherapy with bacterial vaccines. New York Cancer Research Institute, Inc. Monograph #12, New York, 1973.
Nauts, H.C.: Bacterial products in the treatment of cancer: past, present and future. In Bacteria and Cancer, J. Jeljaszewicz, G. Pulverer & W. Roszkowski, Proc. International Colloquium on Bacteria and Cancer, Cologne, Germany, March 16–18,1982. London/New York, Academic Press, 1982, pp. 1–25.
Beebe, S.P. & Tracy, M.: The treatment of experimental tumors with bacterial toxins. J.A.M.A. 49: 1493–1498, 1907.
Coley, W.B. & Coley, B.L.: Primary malignant tumors of the long bones; end results in one hundred and seventy operable cases. Ann. Surg. 13: 779–836, 1926; 14: 63–141, 1927.
Coley, W.B.: Endothelioma, or Ewing’s tumor. Am. J. Surg. 27: 7–18, 1935.
Miller, T.N. & Nicholson, J.T.: End results in reticulum cell sarcoma.of bone treated by toxin therapy alone or combined with surgery and/or radiation (47 cases) or with concurrent infection (5 cases). Cancer 27: 524–548, 1971.
Coley, W.B.: Diagnosis and treatment of bone sarcoma. Glasgow, M. J. 126:49–86; 128–164, 1936.
Thomson, J.F.: Radiation protection in mammals. Reinhold Publishing Corporation, New York, p. 178, 1962.
Ainsworth, E.J. & Forbes, P.D.: The effect of Pseudomonas pyrogen on survival of irradiated mice. Radiation Research 14:767–774, 1961, and personal communications.
Ainsworth, E.J.: The effect of pyrogen dose in radiation protection. Radiation Research 14: 446–447, 1961.
Coley, W.B.: The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus of erysipelas and the Bacillus prodigiosus). Practitioner (London) 83:589–613, 1909. (Also in Proc. Royal Soc, Med., Surg., Sect. 3:1–48, 1909–1910. (Abst. in Brit M.J. 2: 144–145, 1909 ).
Coley, W.B.: The treatment of cancer. Guys’ Hosp. Gag. 26: 7–14, 1911.
Nauts, H.C.: Immunology of Cancer –– The Pioneer Work of Coley. Presented at: International Symposium on Endotoxin: Structural Aspects and Immunobiology of Host Responses, Riva del Sole, Giovinazzo (Bari), Italy, May 29–June 1, 1986.
Old, L.J.: Tumor Necrosis Factor. First identified because of its anticancer activity, the factor is now recognized to be one of a family of proteins that orchestrate the body’s remarkable complex response to injury and infection. Scientific American: 59–75, May, 1988.
Coley, W.B.: Office records 1892–1936.
Coley, W.B.: The treatment of malignant inoperable tumors with the mixed toxins of erysipelas and Bacillus prodigiosus, with a brief report of 80 cases successfully treated with the toxins from 1893–1914. Brussels, M. Weissenbruch, 172 p., 1914.
Coley, W.B.: Prognosis and treatment of giant–cell sarcoma, based on a further study of end results in 69 cases. Ann. Surg. 86: 641–665, 1927.
Coley, W.B.: End results in Hodgkin’s disease or lymphosarcoma treated by mixed toxins of erysipelas and Bacillus prodigiosus, alone or combined with radiation. Trans. Amer. Surg. Assn. 46:331–357, 1928. (also in Ann. Surg. 88: 641–667, 1928 ).
Johnston, B.: Clinical effects of Coley’s toxins. I. A controlled study. Cancer Chem. Repts. 21: 19–41, 1962.
Johnston, B.: Clinical effects of Coley’s toxins. II. A seven–year study. Cancer Chem. Repts. 21: 43–68, 1962.
Havas, H.F., Grosbeck, M.E. & Donnelly, A.J.: Mixed bacterial toxins in the treatment of tumors. I. Methods of preparation and effects on normal or Sarcoma 37–bearing mice. Cancer Res. 18: 141–148, 1958.
Havas, H.F. & Donnelly, A.J.: Mixed bacterial toxins in the treatment of tumors. IV. Response of methylcholanthrene–induced, spontaneous, and transplanted tumors in mice. Cancer Res. 21 (1): 17–25, 1961.
Nauts, H.C.: Multiple Myeloma: Beneficial effects of acute infections or immunotherapy (bacterial vaccines). Cancer Research Institute, Inc., Monograph #13, New York, 1975.
Kempin, S. et al: Improved remission rate and duration in nodular non–Hodgkin’s lymphoma (NNHL) with the use of mixed bacterial vaccine (MBV). Trans. Amer. Soc. Clin. Oncol. 22: 514, 1981.
Kempin, S. et al: Combined modality therapy of advanced nodular lymphomas (NL). The role of non–specific immunotherapy (MBC) as an important determinant of response and survival. ASCO extract, May, 1983.
Zheren, G. & Nauts, H.C.: Pilot study of mixed bacterial vaccine (MBV) on pediatric cancers: 57 cases. In manuscript.
Tang, Z.: Experimental and clinical studies on mixed bacterial vaccine in the treatment of primary liver cancer as adjuvant. In manuscript.
Waisbren, B.A., Sr.: Observations on the combined systemic administration of mixed bacterial vaccine, Bacillus Calmette—Guerin, transfer factor, and lymphoblastoid lymphocytes to patients with cancer, 1974–1985. J. Biol. Response Modifiers 6:1–19, 1987, and Personal Communications, 1977–1989.
Weinberg, E.G.: Iron withholding: a defense against infection and neoplasia. Physiological Reviews 64: 65–102, 1984.
Torrance, J.D., Charlton, R.W., Simon, M.O. et al: The mechanism of endotoxin induced hypoferraemia. Scand. J. Haematol. 21: 403–410, 1978.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Plenum Press, New York
About this chapter
Cite this chapter
Nauts, H.C., McLaren, J.R. (1990). Coley Toxins — The First Century. In: Bicher, H.I., McLaren, J.R., Pigliucci, G.M. (eds) Consensus on Hyperthermia for the 1990s. Advances in Experimental Medicine and Biology, vol 267. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5766-7_52
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5766-7_52
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5768-1
Online ISBN: 978-1-4684-5766-7
eBook Packages: Springer Book Archive